AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
metaraminol ๐ถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1721 | 54-49-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A sympathomimetic agent that acts predominantly at alpha-1 adrenergic receptors. It has been used primarily as a vasoconstrictor in the treatment of HYPOTENSION.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 50 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 49.82 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK2,PIK3CB,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,ZAP70 | 34 | |||
| kinase-selectivity-class | AXL,EIF2AK3,EPHB4,GRK2,MAP2K6 | 5 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 29, 1954 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Mental status changes postoperative | 71.86 | 52.80 | 9 | 512 | 189 | 90627737 |
| Confusion postoperative | 69.72 | 52.80 | 9 | 512 | 242 | 90627684 |
| Stress cardiomyopathy | 64.42 | 52.80 | 15 | 506 | 13340 | 90614586 |
| Maternal exposure during delivery | 57.45 | 52.80 | 11 | 510 | 3835 | 90624091 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Respiratory failure | 78.12 | 68.42 | 30 | 264 | 128102 | 42492939 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anaphylactic reaction | 77.91 | 49.78 | 30 | 803 | 114270 | 110474196 |
| Respiratory failure | 71.71 | 49.78 | 34 | 799 | 215298 | 110373168 |
| Mental status changes postoperative | 60.31 | 49.78 | 8 | 825 | 201 | 110588265 |
| Confusion postoperative | 55.78 | 49.78 | 8 | 825 | 360 | 110588106 |
| Stress cardiomyopathy | 52.98 | 49.78 | 14 | 819 | 15792 | 110572674 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C01CA09 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES Adrenergic and dopaminergic agents |
| MeSH PA | D000316 | Adrenergic alpha-Agonists |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D013566 | Sympathomimetics |
| MeSH PA | D014662 | Vasoconstrictor Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D058646 | Adrenergic alpha-1 Receptor Agonists |
| CHEBI has role | CHEBI:35524 | sympathomimetic agent |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35569 | ฮฑ-adrenergic agonist |
| CHEBI has role | CHEBI:50514 | vasoconstrictor agent |
Related Drugs by ATC class:
C01CA Adrenergic and dopaminergic agents 25 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Low blood pressure | indication | 45007003 | |
| Priapism | off-label use | 6273006 | DOID:9286 |
๐ถ Veterinary Drug Use
None
๐ถ Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.51 | acidic |
| pKa2 | 12.54 | acidic |
| pKa3 | 8.86 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Alpha-1A adrenergic receptor | GPCR | AGONIST | WOMBAT-PK | CHEMBL | |||||
| Macrophage migration inhibitory factor | Cytokine | Ki | 4.11 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4017958 | VUID |
| N0000178937 | NUI |
| D01019 | KEGG_DRUG |
| 33402-03-8 | SECONDARY_CAS_RN |
| 4017958 | VANDF |
| 4019818 | VANDF |
| C0025575 | UMLSCUI |
| CHEBI:6794 | CHEBI |
| CHEMBL1201319 | ChEMBL_ID |
| DB00610 | DRUGBANK_ID |
| CHEMBL2062262 | ChEMBL_ID |
| D008680 | MESH_DESCRIPTOR_UI |
| 5906 | PUBCHEM_CID |
| 34 | INN_ID |
| 7229 | IUPHAR_LIGAND_ID |
| 818U2PZ2EH | UNII |
| 6805 | RXNORM |
| 5061 | MMSL |
| d00702 | MMSL |
| 001824 | NDDF |
| 004735 | NDDF |
| 372728001 | SNOMEDCT_US |
| 41015006 | SNOMEDCT_US |
| 58461000 | SNOMEDCT_US |
Pharmaceutical products:
None